COMPANY PROFILE // THE 014 REPORT
Black Diamond Therapeutics, Inc.
BDTX (Nasdaq) · Formerly: Aset Therapeutics, Inc.
Assembled from 3 government sources in 0.2 s
FLAGS · DISCLOSURE · SUMMARY
Missing or hidden
No flag from the records checked. 25 of 26 lists and sources checked came back clear (panel below).
✓ SEC filings✓ State registrationpossible match✗ LEI✗ SAM registration✗ IRS return✗ Website✗ Lobbying registration
No LEI, no SAM registration, no IRS return, no website, no lobbying registration on record.
Black Diamond Therapeutics, Inc. is an SEC-registered operating company in biological products, (no diagnostic substances), based in Cambridge, MA; listed as BDTX (Nasdaq).[source] It reported revenue of $70.0 million for the fiscal year ended 2025-12-31.[source] It has filed 39 documents with the SEC in the last 12 months; the latest is Form 10-Q, filed 2026-11-10.[source] Its largest institutional holders on 13F filings are NEA Management Company, LLC, BlackRock, Inc., VANGUARD CAPITAL MANAGEMENT LLC (as of 2026-06-30).[source] 25 of 26 lists and sources checked came back clear; the rest are listed with their result.[source]
- red0
- amber0
- info0
- NEA Management Company, LLC$8.2M
- BlackRock, Inc.$7.2M
- VANGUARD CAPITAL MANAGEMENT LLC$3.9M
- RENAISSANCE TECHNOLOGIES LLC$3.6M
- Defilade Capital Management, L.P.$3.1M
- DIMENSIONAL FUND ADVISORS LP$2.5M
- GEODE CAPITAL MANAGEMENT, LLC$2.3M
- Connor, Clark & Lunn Investment Management Ltd.$2.0M
RECORD · WEB
Ask about this entity
Answers come from this 014 first; every line is marked RECORD (our record, linked) or WEB (a web page, credited and linked).
PEOPLE · COUNSEL · LINKS
Leadership, advisers and links
Officers and directors (Forms 3, 4, 5)
- Buck Elizabeth · CHIEF SCIENTIFIC OFFICER (Officer) · latest Form 4 2026-01-23 · filing · LinkedIn search
- Hatzis-Schoch Brent · SEE REMARKS (Officer) · latest Form 4 2026-01-23 · filing · LinkedIn search
- Jones Erika · SEE REMARKS (Officer) · latest Form 4 2026-01-23 · filing · LinkedIn search
- Velleca Mark A. · PRESIDENT & CEO (Director,Officer) · latest Form 4 2026-01-23 · filing · LinkedIn search
- Yurasov Sergey · CHIEF MEDICAL OFFICER (Officer) · latest Form 4 2026-01-23 · filing · LinkedIn search
- Behbahani Ali · Director · latest Form 4 2026-03-20 · filing · LinkedIn search
- Campbell Shannon · Director · latest Form 4 2025-06-12 · filing · LinkedIn search
- Dhingra Kapil · Director · latest Form 4 2025-06-12 · filing · LinkedIn search
- Kulkarni Samarth · Director · latest Form 4 2025-06-12 · filing · LinkedIn search
- Menzel Garry E · Director · latest Form 4 2025-06-12 · filing · LinkedIn search
- Raman Prakash · Director · latest Form 4 2026-03-20 · filing · LinkedIn search
As reported to the SEC by the insiders themselves; SEC insider transactions data sets (Forms 3, 4, 5): 2026q1, 2025q4, 2025q3, 2025q2.
Legal counsel, as publicly named
- GOODWIN PROCTER LLP · Exhibit 5.1 legal opinion, S-8 filed 2026-03-16
EVERY LIST AND SOURCE · DATED
Checked and clear
26 lists and sources checked: 25 CLEAR, 1 POSSIBLE MATCH, 0 MATCH. Screening lists are checked when this 014 is built; the enforcement and registry sources at the last company-engine build. Each date is the date of that check.
EVERY IDENTIFIER · LINKED
ID crosswalk
| Identifier | Value | Record |
|---|---|---|
| SEC CIK | 0001701541 | source |
| EIN | 81-4254660 | source |
| NY DOS ID | 5055863 | record |
| Connecticut business ID | 2772026 | record |
| Business address (SEC) | 245 FIRST STREET, 18TH FLOOR, CAMBRIDGE, MA, 02142 | source |
Does not exist in the records we hold: LEI, UEI, FDIC certificate.
EACH FEEDS WATCH
Dates coming up
- 2027-03-31 · in 129 days · Next 10-K due (period ended 2026-12-31; Non-accelerated filer<br>Smaller reporting company) (computed from the fiscal year end and filer status)
- 2027-05-15 · in 174 days · Next 10-Q due (period ended 2027-03-31; Non-accelerated filer<br>Smaller reporting company) (computed from the fiscal year end and filer status)
PEERS BY SIC CODE
Industry context
SIC 2836 (biological products, (no diagnostic substances)): 183 companies in our records share this code.
federal dollars
lobbying filings
SEC filings in 12 months
flags
Peers, each with its 014
- AMGEN INC · 123 SEC filings in 12 months · 1 flag · $507.4M federal (possible match)
- Vir Biotechnology, Inc. · 117 SEC filings in 12 months · 1 flag · $65.9M federal (possible match)
- Vericel Corp · 109 SEC filings in 12 months · 1 flag · $37.3M federal (possible match)
- Coherus Oncology, Inc. · 53 SEC filings in 12 months · 3 flags · $11.8M federal (possible match)
- BIO-TECHNE Corp · 77 SEC filings in 12 months · 1 flag · $6.6M federal (possible match)
- Twist Bioscience Corp · 337 SEC filings in 12 months · 2 flags · $5.9M federal (possible match)
- Adaptive Biotechnologies Corp · 185 SEC filings in 12 months · 1 flag · $1.9M federal (possible match)
- AGENUS INC · 82 SEC filings in 12 months · 3 flags · $613K federal (possible match)
- REPLIGEN CORP · 89 SEC filings in 12 months · 1 flag · $457K federal (possible match)
- Revolution Medicines, Inc. · 171 SEC filings in 12 months · 2 flags · $15K federal (possible match)
- RECURSION PHARMACEUTICALS, INC. · 174 SEC filings in 12 months · 1 flag
- GILEAD SCIENCES, INC. · 173 SEC filings in 12 months
ADDRESS · ZIP CODE
Location context
At the same address (2)
- NANOBIOSYM EDUCATION AND RESEARCH INSTITUTE INC · IRS-registered organization
SHARED PEOPLE · SHARED ADDRESS
Network neighbours
Shared directors and officers
- Arcellx, Inc. · Ali Behbahani, M.D.
- CRISPR Therapeutics AG · Ali Behbahani, M.D.
- CRISPR Therapeutics AG · Samarth Kulkarni, Ph.D
- Centessa Pharmaceuticals plc · Samarth Kulkarni, Ph.D
- Korro Bio, Inc. · Ali Behbahani, M.D.
- Monte Rosa Therapeutics, Inc. · Ali Behbahani, M.D.
- Nkarta, Inc. · Ali Behbahani, M.D.
- Olema Oncology, Inc. · Prakash Raman, Ph.D.
- Oruka Therapeutics, Inc. · Samarth Kulkarni, Ph.D
- Replimune Group, Inc. · Kapil Dhingra, M.B.B.S.
- SpyGlass Pharma, Inc. · Ali Behbahani, M.D.
- Trevi Therapeutics, Inc. · Ali Behbahani, M.D.
- Zentalis Pharmaceuticals, Inc. · Shannon Campbell
EVERY SOURCE · NEWEST FIRST
One timeline
- 2026-11-10 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-11-10 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-08-05 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-08-05 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-06-29 filing 8-K items 5.07 · SEC EDGAR
- 2026-05-21 filing 8-K items 7.01,8.01,9.01 · SEC EDGAR
- 2026-05-07 filing Quarterly report (10-Q) · SEC EDGAR
- 2026-05-07 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-04-29 filing ARS · SEC EDGAR
- 2026-04-29 filing DEFA14A · SEC EDGAR
- 2026-04-29 filing Proxy statement · SEC EDGAR
- 2026-03-16 filing S-8 · SEC EDGAR
- 2026-03-16 filing Annual report (10-K) · SEC EDGAR
- 2026-03-16 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2026-01-23 insider First Form 3/4/5 on record for Buck Elizabeth (CHIEF SCIENTIFIC OFFICER) · SEC Forms 3/4/5
- 2026-01-23 insider First Form 3/4/5 on record for Hatzis-Schoch Brent (SEE REMARKS) · SEC Forms 3/4/5
- 2026-01-23 insider First Form 3/4/5 on record for Jones Erika (SEE REMARKS) · SEC Forms 3/4/5
- 2026-01-23 insider First Form 3/4/5 on record for Velleca Mark A. (PRESIDENT & CEO) · SEC Forms 3/4/5
- 2026-01-23 insider First Form 3/4/5 on record for Yurasov Sergey (CHIEF MEDICAL OFFICER) · SEC Forms 3/4/5
- 2025-12-03 filing EFFECT · SEC EDGAR
- 2025-12-03 filing 8-K items 2.02,7.01,8.01,9.01 · SEC EDGAR
- 2025-12-01 filing CORRESP · SEC EDGAR
- 2025-11-13 filing S-3 · SEC EDGAR
- 2025-11-06 filing Quarterly report (10-Q) · SEC EDGAR
- 2025-11-06 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2025-08-07 filing Quarterly report (10-Q) · SEC EDGAR
- 2025-08-07 filing 8-K items 2.02,9.01 · SEC EDGAR
- 2025-06-12 filing 8-K items 5.07 · SEC EDGAR
- 2025-06-12 insider First Form 3/4/5 on record for Behbahani Ali (Director) · SEC Forms 3/4/5
- 2025-06-12 insider First Form 3/4/5 on record for Campbell Shannon (Director) · SEC Forms 3/4/5
122 earlier entries
- 2025-06-12 insider First Form 3/4/5 on record for Dhingra Kapil (Director)
- 2025-06-12 insider First Form 3/4/5 on record for Kulkarni Samarth (Director)
- 2025-06-12 insider First Form 3/4/5 on record for Menzel Garry E (Director)
- 2025-06-12 insider First Form 3/4/5 on record for Raman Prakash (Director)
- 2025-05-12 filing Quarterly report (10-Q)
- 2025-05-12 filing 8-K items 2.02,9.01
- 2025-04-18 filing ARS
- 2025-04-18 filing DEFA14A
- 2025-04-18 filing Proxy statement
- 2025-03-19 filing 8-K items 1.01,7.01,9.01
- 2025-03-06 filing S-8
- 2025-03-06 filing Annual report (10-K)
- 2025-03-06 filing 8-K items 2.02,9.01
- 2024-11-05 filing Quarterly report (10-Q)
- 2024-11-05 filing 8-K items 2.02,9.01
- 2024-10-07 officer change 8-K items 5.02,7.01,8.01,9.01
- 2024-09-23 filing 8-K items 7.01,8.01,9.01
- 2024-08-08 filing SC 13D/A
- 2024-08-06 filing Quarterly report (10-Q)
- 2024-08-06 filing 8-K items 2.02,9.01
- 2024-07-31 filing 144
- 2024-07-26 filing 144
- 2024-07-16 filing 144
- 2024-07-11 filing 144
- 2024-07-09 filing 144
- 2024-06-28 filing 144
- 2024-06-27 filing 144
- 2024-06-26 filing 144
- 2024-06-24 filing 144
- 2024-06-21 filing 144
- 2024-06-20 filing 144
- 2024-06-20 filing 144
- 2024-06-18 filing 144
- 2024-06-14 filing 144
- 2024-06-13 filing 144
- 2024-06-12 filing 144
- 2024-06-06 filing 8-K items 5.03,5.07,9.01
- 2024-05-13 filing SC 13D/A
- 2024-05-09 filing SC 13D/A
- 2024-05-09 filing Quarterly report (10-Q)
- 2024-05-09 filing 8-K items 2.02,9.01
- 2024-04-24 filing ARS
- 2024-04-24 filing DEFA14A
- 2024-04-24 filing Proxy statement
- 2024-04-12 filing PRE 14A
- 2024-04-11 officer change 8-K items 5.02,7.01,9.01
- 2024-03-12 filing S-8
- 2024-03-12 filing Annual report (10-K)
- 2024-03-12 filing 8-K items 2.02,9.01
- 2024-01-18 officer change 8-K items 5.02,9.01
- 2024-01-04 filing 8-K items 7.01,9.01
- 2023-12-13 filing 8-K items 7.01,8.01,9.01
- 2023-11-09 filing SC 13D/A
- 2023-11-06 filing Quarterly report (10-Q)
- 2023-11-06 filing 8-K items 2.02,9.01
- 2023-09-18 officer change 8-K items 5.02,7.01,9.01
- 2023-08-11 filing Quarterly report (10-Q)
- 2023-08-11 filing 8-K items 2.02,9.01
- 2023-06-30 filing 8-K items 1.01,9.01
- 2023-06-30 filing 424B5
- 2023-06-29 filing 424B5
- 2023-06-27 filing 144
- 2023-06-27 filing 8-K items 7.01,8.01,9.01
- 2023-05-16 filing 8-K items 5.07
- 2023-05-09 filing Quarterly report (10-Q)
- 2023-05-09 filing 8-K items 2.02,9.01
- 2023-04-04 filing ARS
- 2023-04-04 filing DEFA14A
- 2023-04-04 filing Proxy statement
- 2023-03-09 filing S-8
- 2023-03-09 filing Annual report (10-K)
- 2023-03-09 filing 8-K items 2.02,9.01
- 2022-12-19 officer change 8-K items 5.02,7.01,9.01
- 2022-12-12 filing 8-K items 7.01,8.01,9.01
- 2022-11-22 filing EFFECT
- 2022-11-18 filing CORRESP
- 2022-11-17 filing UPLOAD
- 2022-11-14 filing S-3
- 2022-11-08 filing Quarterly report (10-Q)
- 2022-11-08 filing 8-K items 2.02,9.01
- 2022-08-09 filing Quarterly report (10-Q)
- 2022-08-09 filing 8-K items 2.02,9.01
- 2022-06-07 filing 8-K items 5.07
- 2022-05-11 filing Quarterly report (10-Q)
- 2022-05-11 filing 8-K items 2.02,9.01
- 2022-04-28 filing DEFA14A
- 2022-04-28 filing Proxy statement
- 2022-04-25 filing 8-K items 7.01,9.01
- 2022-04-07 officer change 8-K items 5.02,9.01
- 2022-03-17 filing S-8
- 2022-03-17 filing Annual report (10-K)
- 2022-03-17 filing 8-K items 2.02,9.01
- 2022-01-10 filing 8-K items 8.01
- 2022-01-10 filing 8-K items 7.01,8.01,9.01
- 2021-11-22 officer change 8-K items 5.02
- 2021-11-08 filing Quarterly report (10-Q)
- 2021-11-08 filing 8-K items 2.02,9.01
- 2021-08-12 filing Quarterly report (10-Q)
- 2021-08-12 filing 8-K items 2.02,9.01
- 2021-08-10 officer change 8-K items 5.02,9.01
- 2021-08-05 officer change 8-K items 5.02
- 2021-06-22 filing 8-K items 5.07
- 2021-05-19 filing 8-K items 7.01,8.01,9.01
- 2021-05-07 filing Quarterly report (10-Q)
- 2021-05-07 filing 8-K items 2.02,9.01
- 2021-04-29 filing DEFA14A
- 2021-04-27 filing Proxy statement
- 2021-04-21 filing 8-K items 5.08
- 2021-03-25 filing S-8
- 2021-03-25 filing Annual report (10-K)
- 2021-03-25 filing 8-K items 2.02,9.01
- 2021-03-15 filing 8-K items 8.01
- 2021-02-01 filing 8-K items 1.01
- 2021-02-01 filing S-3ASR
- 2021-01-20 officer change 8-K items 5.02,9.01
- 2020-12-03 filing SC 13D/A
- 2020-11-23 filing SC 13D/A
- 2020-11-10 filing Quarterly report (10-Q)
- 2020-11-10 filing 8-K items 2.02,9.01
- 2020-09-29 officer change 8-K items 5.02,9.01
- 2020-09-25 filing SC 13D/A
- 2018-01-04 name change Name changed from Aset Therapeutics, Inc.
RENDERED FROM THIS PAGE
Relationship graph
Holders from 13F filings, subsidiaries from the GLEIF tree (by LEI), lobbying firms from LDA (possible match), agencies from USAspending, people from Forms 3/4/5, counsel from Exhibit 5.1, shared boards from Forms 3/4/5.
DATA MOTION // NEWEST FIRSTWhat changed
- 2026-11-10 (within 30 days) 10-Q filed
- 2026-11-10 (within 30 days) 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-09-08 (older) Form 5500 received for plan year ending 2025-12-31 (plan no. 001)
- 2026-08-05 (older) 10-Q filed
- 2026-08-05 (older) 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-06-29 (older) 8-K filed: Item 5.07 shareholder vote
- 2026-05-21 (older) 8-K filed: Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-05-07 (older) 10-Q filed
Dot rule: red = within 7 days, amber = within 30 days, green = older. Measured against 2026-11-22; the colour is also written out in words.
COUNTS FROM THIS PAGERelationships at a glance
PRICE · FILINGS · POSTS · NEWSMarket & news
- Price
- NASDAQ:BDTX The chart widget (TradingView) shows the price and the previous session's close. Seraphix publishes no price of its own.
- Open in
Open in…
Price and chart
News
Analyst estimates and earnings
Institutional holders
Short interest
Official social
Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.
- Financials
- Filed figures: published SEC values, each linked to its filing.
- Official posts
- Links to posts from the company's and agencies' verified accounts: not connected yet.
- News
- Article links (headline, date, link): not connected yet.
EVERY RESOLVED IDENTIFIER1. Identity
4 possible matches held apart, matched by name only, not counted above.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| SEC CIK | 1701541 | id:sec-anchor: the SEC registrant record of this company | SEC EDGAR |
| Ticker / exchange | BDTX / Nasdaq | SEC company record: ticker and exchange as listed on the SEC company record | SEC EDGAR |
| EIN | 814254660 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001701541 | SEC EDGAR / IRS |
| CUSIP | 09203E105 | carried on the SEC-anchored record: listed in the identifiers of sx:sec:0001701541 | SEC EDGAR |
possible match: matched by name only, not merged (1)
Identifiers carried by records that share the company's exact name. Not merged into the identity above.
| Identifier | Value | How it was resolved | Source |
|---|---|---|---|
| EPA FRS id | 110070913429 (BLACK DIAMOND THERAPEUTICS) | name-exact: exact name match to 'Black Diamond Therapeutics, Inc.' (no other entity shares the name) | EPA ECHO facilities |
AS FILED · EACH WITH ITS DATE AND FILING2. Filed figures
Key figures (annual filing)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Revenue (fiscal year ended 2025-12-31) | $70,000,000 | 2025-12-31 | 10-K, XBRL RevenueFromContractWithCustomerIncludingAssessedTax | as filed | 2026-11-22 00:37 UTC | Report an error |
| Net income (loss) (fiscal year ended 2025-12-31) | $22,367,000 | 2025-12-31 | 10-K, XBRL NetIncomeLoss | as filed | 2026-11-22 00:37 UTC | Report an error |
| Total assets (at 2025-12-31) | $143,010,000 | 2025-12-31 | 10-K, XBRL Assets | as filed | 2026-11-22 00:37 UTC | Report an error |
| Stockholders' equity (at 2025-12-31) | $112,211,000 | 2025-12-31 | 10-K, XBRL StockholdersEquity | as filed | 2026-11-22 00:37 UTC | Report an error |
| Cash and cash equivalents (at 2025-12-31) | $20,990,000 | 2025-12-31 | 10-K, XBRL CashAndCashEquivalentsAtCarryingValue | as filed | 2026-11-22 00:37 UTC | Report an error |
Company profile facts (SEC)
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| SEC entity type | operating | 2026-11-10 | SEC EDGAR company profile | as filed | 2026-11-22 00:37 UTC | Report an error |
| SIC industry | 2836 Biological Products, (No Diagnostic Substances) | 2026-11-10 | SEC EDGAR company profile | as filed | 2026-11-22 00:37 UTC | Report an error |
| Fiscal year end (MMDD) | 1231 | 2026-11-10 | SEC EDGAR company profile | as filed | 2026-11-22 00:37 UTC | Report an error |
| Business address | 245 FIRST STREET, 18TH FLOOR, CAMBRIDGE, MA, 02142 | 2026-11-10 | SEC EDGAR company profile | as filed | 2026-11-22 00:37 UTC | Report an error |
| Exchanges | Nasdaq | 2026-11-10 | SEC EDGAR company profile | as filed | 2026-11-22 00:37 UTC | Report an error |
Other filed values
| Figure | Value | Period or as of | Source | Basis | Retrieved | Report |
|---|---|---|---|---|---|---|
| Operating cash flow (fiscal year ended 2025-12-31) | $29,614,000 | 2025-12-31 | 10-K, XBRL NetCashProvidedByUsedInOperatingActivities | as filed | 2026-11-22 00:37 UTC | Report an error |
| Capital expenditures (property, plant and equipment) (fiscal year ended 2024-12-31) | $0 | 2024-12-31 | 10-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment | as filed | 2026-11-22 00:37 UTC | Report an error |
| Operating lease liabilities (at 2025-12-31) | $18,781,000 | 2025-12-31 | 10-K, XBRL OperatingLeaseLiability | as filed | 2026-11-22 00:37 UTC | Report an error |
| Form D total offering amount (D filed 2019-12-06) | $84,999,941 | 2019-12-06 | D | as filed | 2026-11-22 00:37 UTC | Report an error |
| Form D total amount sold (D filed 2019-12-06) | $84,999,941 | 2019-12-06 | D | as filed | 2026-11-22 00:37 UTC | Report an error |
| Form D industry group | Biotechnology | 2019-12-06 | D | as filed | 2026-11-22 00:37 UTC | Report an error |
| Form D revenue range | Decline to Disclose | 2019-12-06 | D | as filed | 2026-11-22 00:37 UTC | Report an error |
| Form D date of first sale | 2019-11-25 | 2019-12-06 | D | as filed | 2026-11-22 00:37 UTC | Report an error |
| Plan (pension, plan no. 001) | BLACK DIAMOND THERAPEUTICS, INC. RETIREMENT PLAN: 68 participants | 2025-12-31 | DOL EBSA Form 5500 public datasets (dataset) | as filed | 2026-11-22 00:37 UTC | Report an error |
Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-10 · accession 0001701541-26-000032
| Item | Value | Period | Form | Filed | Accession | Retrieved | Report |
|---|---|---|---|---|---|---|---|
| Revenue | $0 | 3 months ended 2026-09-30 | 10-Q | 2026-11-10 | 0001701541-26-000032 | 2026-11-22 00:37 UTC | Report an error |
| Net income (loss) | -$10,012,000 | 3 months ended 2026-09-30 | 10-Q | 2026-11-10 | 0001701541-26-000032 | 2026-11-22 00:37 UTC | Report an error |
| Cash and cash equivalents | $15,084,000 | at 2026-09-30 | 10-Q | 2026-11-10 | 0001701541-26-000032 | 2026-11-22 00:37 UTC | Report an error |
Values as filed in XBRL (SEC company facts); quarterly values are the filer's own 3-month figures, never derived.
No estimates: every value is as filed and links to the filing it came from.
Registration: the SEC filer status is under "Company profile facts (SEC)" above. SAM.gov registration status: not held yet.
NEWEST FIRST · EACH LINKS TO ITS FILING3. Registration and filing timeline
- 2026-11-10 Filing 10-Q filed
- 2026-11-10 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-09-08 Filing Form 5500 received for plan year ending 2025-12-31 (plan no. 001)
- 2026-08-05 Filing 10-Q filed
- 2026-08-05 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-06-29 Filing 8-K filed: Item 5.07 shareholder vote
- 2026-05-21 Filing 8-K filed: Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2026-05-07 Filing 10-Q filed
- 2026-05-07 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2026-04-29 Filing ARS filed
- 2026-04-29 Filing DEFA14A filed
- 2026-04-29 Filing DEF 14A filed
- 2026-03-16 Filing S-8 filed (FORM S-8)
- 2026-03-16 Filing 10-K filed
- 2026-03-16 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2025-12-03 Filing EFFECT filed
- 2025-12-03 Filing 8-K filed: Item 2.02 results of operations; Item 7.01 Regulation FD disclosure; Item 8.01 other event; Item 9.01 exhibits
- 2025-12-01 Filing CORRESP filed
- 2025-11-13 Filing S-3 filed
- 2025-11-06 Filing 10-Q filed
- 2025-11-06 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2025-08-07 Filing 10-Q filed
- 2025-08-07 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2025-06-12 Filing 8-K filed: Item 5.07 shareholder vote
- 2025-05-12 Filing 10-Q filed
2 earlier entries
- 2025-05-12 Filing 8-K filed: Item 2.02 results of operations; Item 9.01 exhibits
- 2021-01-01 Record plan effective date: BLACK DIAMOND THERAPEUTICS, INC. RETIREMENT PLAN
8-K item text, as filed (excerpts)
- 2026-11-10 8-K Item 2.02, Results of Operations and Financial Condition
On November 10, 2026, Black Diamond Therapeutics, Inc. announced its financial results for the nine months ended September 30, 2026. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific… the 8-K · retrieved 2026-11-22 00:37 UTC - 2026-08-05 8-K Item 2.02, Results of Operations and Financial Condition
On August 5, 2026, Black Diamond Therapeutics, Inc. announced its financial results for the six months ended June 30, 2026. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such… the 8-K · retrieved 2026-11-22 00:37 UTC
Each excerpt is the first part of the item's own text, copied as filed and cut at a word; the filing has the rest.
POSSIBLE MATCHES · GROUPED BY SOURCE8. Enforcement by agency
EPA ECHO facilities (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchBLACK DIAMOND THERAPEUTICS · exact name match to 'Black Diamond Therapeutics, Inc.' (no other entity shares the name) · sx:epa:110070913429 Compare
Each record's own page holds its date and the agency document. Matched by exact name only; none of these is counted in the headline.
AS FILED · LARGEST HOLDERS10. 13F institutional holders
| Rank | Holder (13F filer) | Value held | As of | Source | Retrieved | Report |
|---|---|---|---|---|---|---|
| 1 | NEA Management Company, LLC | $8,230,200 | 2026-06-30 | SEC 13F filing | 2026-11-22 00:37 UTC | Report an error |
| 2 | BlackRock, Inc. | $7,246,613 | 2026-06-30 | SEC 13F filing | 2026-11-22 00:37 UTC | Report an error |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | $3,931,750 | 2026-06-30 | SEC 13F filing | 2026-11-22 00:37 UTC | Report an error |
| 4 | RENAISSANCE TECHNOLOGIES LLC | $3,630,429 | 2026-06-30 | SEC 13F filing | 2026-11-22 00:37 UTC | Report an error |
| 5 | Defilade Capital Management, L.P. | $3,098,748 | 2026-06-30 | SEC 13F filing | 2026-11-22 00:37 UTC | Report an error |
| 6 | DIMENSIONAL FUND ADVISORS LP | $2,525,486 | 2026-06-30 | SEC 13F filing | 2026-11-22 00:37 UTC | Report an error |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | $2,254,419 | 2026-06-30 | SEC 13F filing | 2026-11-22 00:37 UTC | Report an error |
| 8 | Connor, Clark & Lunn Investment Management Ltd. | $2,021,837 | 2026-06-30 | SEC 13F filing | 2026-11-22 00:37 UTC | Report an error |
| 9 | AWM Investment Company, Inc. | $1,850,000 | 2026-06-30 | SEC 13F filing | 2026-11-22 00:37 UTC | Report an error |
| 10 | MARSHALL WACE, LLP | $1,658,714 | 2026-06-30 | SEC 13F filing | 2026-11-22 00:37 UTC | Report an error |
13F as filed: the holder's own report of its position value at the quarter end.
POSSIBLE MATCHES · LICENCES, PERMITS, CITY AND STATE RECORDS13. Permits and local records
3 state and city records carry this company's exact name, from 3 sources. Possible matches only.
Connecticut business registrations (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchBLACK DIAMOND THERAPEUTICS, INC · exact legal name · sx:ctsos:2772026 Compare
ClinicalTrials.gov (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchBlack Diamond Therapeutics, Inc. · exact legal name · sx:ctgov:hc524233756e33df0 Compare
New York corporations (1)
possible match: matched by name only, not merged (1)
Possible match based on name, not a shared identifier. Compare the records.
- possible matchBLACK DIAMOND THERAPEUTICS, INC. · exact legal name · sx:nydos:5055863 Compare
WHAT THIS PAGE READ
Sources
JSON · MCP · API
API and agents
The same profile as JSON: GET /company/1701541.json. The MCP server and the records API return the same data: GET /v1/record/sx:sec:0001701541. Every source URL used is listed in the file.
Get the evidence file, alerts and the API with a free key. Everything on this page stays free to read.